Recent News

• 04.22.2025 - Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey
• 04.22.2025 - Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey
• 04.10.2025 - Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21
• 04.10.2025 - Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21
• 04.08.2025 - Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
• 04.08.2025 - Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
• 03.28.2025 - 60 Degrees Pharmaceuticals Announces 2024 Annual Results
• 03.28.2025 - 60 Degrees Pharmaceuticals Announces 2024 Annual Results
• 02.20.2025 - 60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split
• 02.20.2025 - 60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Recent Filings

• 04.09.2025 - 8-K Current report
• 04.02.2025 - EFFECT Notice of Effectiveness
• 03.27.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.14.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.12.2025 - D Notice of Exempt Offering of Securities
• 02.11.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors